Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pemetrexed in Children With Recurrent Malignancies

NCT00520936 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00520936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00520936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pemetrexed in Children With Recurrent Malignancies
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2007
Completion date
February 28, 2010
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ependymoma, medulloblastoma, neuroblastoma (measurable disease), neuroblastoma (metaiodobenzylguanidine, non-brainstem high-grade glioma, osteosarcoma, positive evaluable), rhabdomyosarcoma, sarcoma, ewing's